Literature DB >> 2572972

The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat. A behavioural and biochemical characterization.

N Waters1, G Pettersson, A Carlsson, K Svensson.   

Abstract

Amperozide (FG 5606; N-ethyl-4-[4',4'-bis(p-fluorophenyl)butyl]-1-piperazinecarboximide ) is a new putatively antipsychotic compound with a postulated 5-HT2 antagonistic profile. Somewhat surprisingly amperozide dose dependently induced a behavioural stimulation in reserpinized and in nonpretreated rats. The behaviour consisted of both forward and backward locomotion as well as forepaw circling and a grooming like behaviour. Since the behavioural pattern clearly differ from that produced by classical dopaminergic or serotonergic agonists (e.g. apomorphine or 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT), and has not been previously reported, we decided to investigate the origin of this effect. In the behavioural paradigms it was not possible to antagonize the amperozide stimulation in reserpinized rats with the dopamine receptor blockers haloperidol, raclopride or R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine, SCH 23390. Neither the 5-HT2 receptor blocking agent ritanserin nor the tryptophan and tyrosine hydroxylase inhibitor DL-3,4-dihydroxy-phenyl-alpha-propylacetamide, H22/54, could block the motoric stimulation or the forepaw circling behaviour produced by amperozide. However, the noradrenaline synthesis inhibitor bis-(4-methyl-1-homopiperazinylthiocarbonyl)-disulfide, FLA 63, as well as the alpha-adrenoceptor antagonist phenoxybenzamine, could partly inhibit the locomotor stimulation. Hence, noradrenaline seems to be, at least in part, involved in the behavioural stimulatory effect of amperozide. Biochemically amperozide had no effect on the dopamine synthesis rate (DOPA formation) in normal or reserpinized animals in the striatal or the limbic brain regions. In reserpinized animals amperozide also failed to antagonize the decrease in DOPA formation after apomorphine and 3-hydroxy-benzylhydrazine HCl, NSD 1015, in these regions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572972     DOI: 10.1007/BF00168964

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Biochemical and electrophysiological studies of the psychotropic compound, amperozide.

Authors:  J T Haskins; E A Muth; T H Andree
Journal:  Brain Res Bull       Date:  1987-10       Impact factor: 4.077

2.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents.

Authors:  N E Andén; M Grabowska; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

3.  On the significance of central noradrenaline for motor activity: experiments with a new dopamine beta-hydroxylase inhibitor.

Authors:  T H Svensson; B Waldeck
Journal:  Eur J Pharmacol       Date:  1969-09       Impact factor: 4.432

Review 4.  GABA-benzodiazepine-barbiturate receptor interactions.

Authors:  R W Olsen
Journal:  J Neurochem       Date:  1981-07       Impact factor: 5.372

5.  Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo.

Authors:  A Carlsson; M Lindqvist
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

6.  Central effects of an inhibitor of tyrosine hydroxylation.

Authors:  H Corrodi; L C Hanson
Journal:  Psychopharmacologia       Date:  1966

7.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

8.  Effects of amperozide on biting behavior and performance in restricted-fed pigs following regrouping.

Authors:  A Björk; N G Olsson; E Christensson; K Martinsson; O Olsson
Journal:  J Anim Sci       Date:  1988-03       Impact factor: 3.159

9.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

10.  Amperozide--a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour.

Authors:  B Gustafsson; E Christensson
Journal:  Pharmacol Toxicol       Date:  1990
View more
  1 in total

1.  Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex.

Authors:  G G Nomikos; M Iurlo; J L Andersson; K Kimura; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.